No Data
No Data
Sarepta Therapeutics | 10-K: FY2024 Annual Report
Express News | Sarepta Therapeutics Announces Call for Applications for the 8TH Annual Route 79, the Duchenne Scholarship Program
Oppenheimer Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $215
Oppenheimer Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $170 to $209
Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program